Balloon Angioplasty is a procedure to enlarge the opening in a blood vessel that has become narrowed or blocked by plaque (a buildup of fat and cholesterol on the inner wall of the blood vessel). A small balloon is filled with air inside the blood vessel to push the plaque against the blood vessel wall and increase the opening.
Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.
Detailed prediction models that project long-term patient mortality following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) surgery can be useful for the heart team when determining the best treatment strategy for individual patients, according to a study in the February 2014 issue of The Annals of Thoracic Surgery.
The chance of surviving a heart attack is far lower in the UK than Sweden, according to a major new study published in The Lancet. The startling findings suggest that more than 11000 lives could have been saved over the past 7 years had UK patients experienced the same care as their Swedish counterparts.
For patients with diabetes and coronary artery disease in more than one artery, treatment with coronary artery bypass graft surgery provided slightly better health status and quality of life between 6 months and 2 years than procedures using drug-eluting stents, although beyond 2 years the difference disappeared, according to a study in the October 16 issue of JAMA.
Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.
The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.
It's no secret that a diet high in fat and sugar can lead to extra fat around the waistline. But it's what the diet will do to a specific type of fat around the heart that caught the attention of a group of Creighton researchers.
In 2012, more than 3 million people had stents inserted in their coronary arteries. These tiny mesh tubes prop open blood vessels healing from procedures like a balloon angioplasty, which widens arteries blocked by clots or plaque deposits.
Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).
In a study that included nearly 6 million Medicare Advantage and Medicare fee-for-service beneficiaries from 12 states, rates of angiography and percutaneous coronary interventions were significantly lower among Medicare Advantage beneficiaries and geographic variation in procedure rates was substantial for both payment types, according to a study in the July 10 issue of JAMA.
Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease.
MD-Procedures like angioplasty, stenting and bypass surgery may save lives, but they also cause excessive inflammation and scarring, which ultimately can lead to permanent disability and even death.
In 2012, more than 3 million people had stents inserted in their coronary arteries. These tiny mesh tubes prop open blood vessels healing from procedures like a balloon angioplasty, which widens arteries blocked by clots or plaque deposits. After about six months, most damaged arteries are healed and stay open on their own. The stent, however, is there for a lifetime.
Drug-eluting stents can keep clogged leg arteries open, preventing amputation of the leg, suggests research being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans.
The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation treatment," which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse.
In a study that included 3.3 million percutaneous coronary intervention procedures, major bleeding after PCI was associated with significantly increased in-hospital mortality, with an estimated 12 percent of deaths after PCI related to bleeding complications, according to a study appearing in the March 13 issue of JAMA.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.